MXPA05013321A - Nuevas moleculas modificadas de corina que tienen secuencias de activacion sustitutiva y sus usos. - Google Patents
Nuevas moleculas modificadas de corina que tienen secuencias de activacion sustitutiva y sus usos.Info
- Publication number
- MXPA05013321A MXPA05013321A MXPA05013321A MXPA05013321A MXPA05013321A MX PA05013321 A MXPA05013321 A MX PA05013321A MX PA05013321 A MXPA05013321 A MX PA05013321A MX PA05013321 A MXPA05013321 A MX PA05013321A MX PA05013321 A MXPA05013321 A MX PA05013321A
- Authority
- MX
- Mexico
- Prior art keywords
- corin molecules
- molecules
- modified corin
- substitute activation
- novel modified
- Prior art date
Links
- 102100037293 Atrial natriuretic peptide-converting enzyme Human genes 0.000 title abstract 6
- 101710133555 Atrial natriuretic peptide-converting enzyme Proteins 0.000 title abstract 6
- 230000004913 activation Effects 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 206010007559 Cardiac failure congestive Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 206010000891 acute myocardial infarction Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000005714 functional activity Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
Esta invencion se refiere a las nuevas moleculas de corina modificada, o fragmentos o derivados de las mismas, que comprenden una secuencia de activacion sustituta. Las moleculas de corina modificada son escindidas en la secuencia de activacion sustituta, con lo cual se generan moleculas de corina modificada, o fragmentos o derivados de las mismas, que muestran la actividad funcional de las moleculas de corina tipo silvestre, de origen natural. Las moleculas de corina modificada pueden ser utilizadas para tratar una variedad de enfermedades o trastornos, incluyendo insuficiencia cardiaca congestiva e infarto agudo al miocardio.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47768303P | 2003-06-11 | 2003-06-11 | |
| PCT/US2004/018669 WO2004111225A1 (en) | 2003-06-11 | 2004-06-09 | Novel modified corin molecules having substitute activation sequences and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA05013321A true MXPA05013321A (es) | 2006-03-09 |
Family
ID=33551745
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA05013321A MXPA05013321A (es) | 2003-06-11 | 2004-06-09 | Nuevas moleculas modificadas de corina que tienen secuencias de activacion sustitutiva y sus usos. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US7176013B2 (es) |
| EP (1) | EP1636356A1 (es) |
| JP (1) | JP2007502132A (es) |
| KR (1) | KR20060022683A (es) |
| CN (2) | CN101109011A (es) |
| AU (1) | AU2004248192A1 (es) |
| BR (1) | BRPI0411353A (es) |
| CA (1) | CA2527361A1 (es) |
| IL (1) | IL172095A0 (es) |
| MX (1) | MXPA05013321A (es) |
| NO (1) | NO20060144L (es) |
| PL (1) | PL379196A1 (es) |
| RU (1) | RU2006100035A (es) |
| WO (1) | WO2004111225A1 (es) |
| ZA (1) | ZA200600224B (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050026255A1 (en) * | 2002-06-25 | 2005-02-03 | Morser John Michael | Corin, a serine protease |
| TW200723151A (en) * | 2005-12-07 | 2007-06-16 | Era Digital Media Co | Business website method |
| WO2009120760A1 (en) * | 2008-03-28 | 2009-10-01 | The Cleveland Clinic Foundation | Corin for treating obesity and diabetes |
| WO2010096658A1 (en) | 2009-02-19 | 2010-08-26 | The Cleveland Clinic Foundation | Corin as a marker for heart failure |
| US10314894B2 (en) * | 2014-02-12 | 2019-06-11 | The Cleveland Clinic Foundation | Treatment of cardio-renal disease using PCSK6 |
| WO2017151453A1 (en) * | 2016-02-29 | 2017-09-08 | Regeneron Pharmaceuticals, Inc. | Rodents having a humanized tmprss gene |
| CN105734070A (zh) * | 2016-04-11 | 2016-07-06 | 苏州大学 | Corin基因变异体及其用途 |
| CN108066286B (zh) * | 2016-11-10 | 2021-06-29 | 复旦大学 | 炔丙基半胱氨酸纳米粒长循环脂质体及其制备方法和用途 |
| CN118530307B (zh) * | 2024-06-14 | 2025-09-09 | 中国人民解放军军事科学院军事医学研究院 | 一种阻断pts途径的多肽及其应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO882226L (no) * | 1987-05-22 | 1988-11-23 | Zymogenetics Inc | Fibrinolytiske proteiner. |
| US5869637A (en) | 1996-07-22 | 1999-02-09 | Incyte Pharmaceuticals, Inc. | Human Kallikrein |
| WO1998024886A1 (en) * | 1996-12-04 | 1998-06-11 | Brigham And Women's Hospital, Inc. | Mast cell protease that cleaves fibrinogen |
| WO1998036054A1 (en) | 1997-02-13 | 1998-08-20 | Amrad Operations Pty. Ltd. | Novel molecules |
| WO1999010503A1 (de) * | 1997-08-22 | 1999-03-04 | Roche Diagnostics Gmbh | Autokatalytisch aktivierbare zymogene vorstufen von proteasen und deren verwendung |
| EP0927764B1 (de) * | 1997-12-03 | 2004-05-26 | Boehringer Mannheim Gmbh | Chimäre Serinproteasen |
| EP1084259B1 (en) | 1998-06-05 | 2008-05-28 | Bayer Schering Pharma Aktiengesellschaft | Corin, a serine protease |
| US6420157B1 (en) * | 1999-04-30 | 2002-07-16 | Ortho-Mcneil Pharmaceutical, Inc. | Zymogen activation system |
| EP1252300B1 (en) | 2000-02-03 | 2011-01-19 | Dendreon Corporation | Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon |
| EP1326882A2 (en) * | 2000-06-19 | 2003-07-16 | Dyax Corp. | Enterokinase cleavage sequences and their use |
| AU8628601A (en) * | 2000-09-04 | 2002-03-22 | Hyo-Joon Kim | Mimetic peptides for epitope of apolipoprotein B-100, concatemer and modified peptides thereof, and the vaccine composition comprising the same |
| FR2831170B1 (fr) * | 2001-10-19 | 2004-03-19 | Inst Nat Sante Rech Med | Proteines c modifiees activables directement par la thrombine |
| WO2004033630A2 (en) * | 2002-10-04 | 2004-04-22 | Schering Aktiengesellschaft | Modified hepsin molecules having a substitute activation sequence and uses thereof |
-
2004
- 2004-06-09 RU RU2006100035/13A patent/RU2006100035A/ru not_active Application Discontinuation
- 2004-06-09 PL PL379196A patent/PL379196A1/pl not_active Application Discontinuation
- 2004-06-09 WO PCT/US2004/018669 patent/WO2004111225A1/en not_active Ceased
- 2004-06-09 US US10/865,978 patent/US7176013B2/en not_active Expired - Fee Related
- 2004-06-09 EP EP04755046A patent/EP1636356A1/en not_active Withdrawn
- 2004-06-09 JP JP2006533746A patent/JP2007502132A/ja active Pending
- 2004-06-09 CN CNA2007101280546A patent/CN101109011A/zh active Pending
- 2004-06-09 AU AU2004248192A patent/AU2004248192A1/en not_active Abandoned
- 2004-06-09 CA CA002527361A patent/CA2527361A1/en not_active Abandoned
- 2004-06-09 MX MXPA05013321A patent/MXPA05013321A/es not_active Application Discontinuation
- 2004-06-09 BR BRPI0411353-5A patent/BRPI0411353A/pt not_active IP Right Cessation
- 2004-06-09 CN CNA2004800230099A patent/CN1836037A/zh active Pending
- 2004-06-09 KR KR1020057023612A patent/KR20060022683A/ko not_active Withdrawn
-
2005
- 2005-11-22 IL IL172095A patent/IL172095A0/en unknown
-
2006
- 2006-01-10 NO NO20060144A patent/NO20060144L/no not_active Application Discontinuation
- 2006-01-10 ZA ZA200600224A patent/ZA200600224B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20050003416A1 (en) | 2005-01-06 |
| WO2004111225A1 (en) | 2004-12-23 |
| CN1836037A (zh) | 2006-09-20 |
| KR20060022683A (ko) | 2006-03-10 |
| IL172095A0 (en) | 2009-02-11 |
| CA2527361A1 (en) | 2004-12-23 |
| RU2006100035A (ru) | 2006-08-27 |
| US7176013B2 (en) | 2007-02-13 |
| CN101109011A (zh) | 2008-01-23 |
| WO2004111225A8 (en) | 2006-04-06 |
| JP2007502132A (ja) | 2007-02-08 |
| PL379196A1 (pl) | 2006-07-24 |
| EP1636356A1 (en) | 2006-03-22 |
| AU2004248192A1 (en) | 2004-12-23 |
| BRPI0411353A (pt) | 2006-07-11 |
| ZA200600224B (en) | 2007-04-25 |
| NO20060144L (no) | 2006-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT3072978T (pt) | 1l1rl-1 como um marcador de doença cardiovascular | |
| WO2003068934A3 (en) | Chimeric molecules for cleavage in a treated host | |
| GB0222495D0 (en) | Compounds | |
| WO2003089601A3 (en) | 3-deoxyglucosone and skin | |
| MX2007002470A (es) | Fenilaminotiazoles sustituidos y su uso. | |
| WO2002032461A3 (en) | Protein c or activated protein c-like molecules | |
| MXPA05013321A (es) | Nuevas moleculas modificadas de corina que tienen secuencias de activacion sustitutiva y sus usos. | |
| MY141528A (en) | Anilinopyrazole derivatives useful for the treatment of diabetes | |
| MXPA04007031A (es) | Derivados benzofurano y benzotiofeno utiles en el tratamiento de desordenes hiper-proliferativos. | |
| WO2004033630A3 (en) | Modified hepsin molecules having a substitute activation sequence and uses thereof | |
| WO2002081745A3 (en) | Genes involved in osteogenesis, and methods of use | |
| WO2006114105A3 (en) | Use of modified factor vii for treating bleeding | |
| WO2004033660A3 (en) | Gene expression profiling from ffpe samples | |
| WO2003070169A3 (en) | Aminodiphosphonate apolipoprotein e modulators | |
| EA200400438A1 (ru) | Применение ирбесартана для изготовления лекарств, которые пригодны для предупреждения или лечения лёгочной гипертонии | |
| ATE533779T1 (de) | Isoliertes photoprotein mtclytin, sowie dessen verwendung | |
| WO1999055859A3 (en) | Cd40-interacting and traf-interacting proteins | |
| WO2004085471A3 (en) | Glp-2 derivatives | |
| AU2002210420A1 (en) | Novel nucleotide sequences coding for the luxr gene | |
| DE50308032D1 (de) | Isoliertes fluoreszierendes protein aus clytia gregaria cgfp, sowie dessen verwendung | |
| TW200505435A (en) | Treatment of ocular disorders | |
| WO2004076414A3 (en) | Novel compounds | |
| EP1639110A4 (en) | RAYGRAP POLISH SPECIFIC PROMOTERS AND EXPRESSION CONSTRUCTS | |
| AU6121901A (en) | Felbamate derived compounds | |
| UA87984C2 (ru) | Повышение уровней масла в растениях |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |